喹硫平治疗帕金森病并发精神障碍的疗效及不良反应观察被引量：2

Quetiapine in the Treatment of Mental Disorders in Parkinson's Disease

下载PDF

导出

摘要目的探讨喹硫平治疗帕金森病(PD)并发精神障碍的疗效及不良反应。方法收集帕金森病合并精神障碍患者100例,治疗组50例,对照组50例,对照组调整抗帕金森药物治疗,治疗组在此基础之上加用喹硫平治疗,观察6周,治疗前后采用UPDRS评定运动功能,精神症状阳性症状量表(SAPS)评价患者精神症状程度,以SAPS减分率评定疗效。结果两组SAPS量表评价比较,幻觉和妄想二项精神症状评分差异有统计学意义评分,治疗组患者治疗前后运动障碍差异无统计学意义,对照组运动障碍有统计学意义。结论喹硫平对PD并发幻觉妄想等阳性精神症状的患者疗效肯定安全,且不加重运动障碍。 Objective To investigate the effect of quetiapine, in the treatment of mental disorders in parkinson＆#39; s disease （PD）. Methods 100 patients with mental disorders in parkinson＆#39;s disease were randomly assigned quetiapine, group and controls group. UPDRS, SAPS scales were tested before treatment and after 6 weeks’ treatment in order to observe symptoms including hallucinosis, deliria and abnormal behavior and dyskinesia. Results Compare with controls group, hallucinosis, deliria and abnormal behavior in quetiapine, group were signiifcant improved （P〈0.05）. Conclusion Quetiapine appears to an effective drug for PD patients with mental disorders, quetiapine is safe for those patients.

作者王银妹

机构地区辽宁省人民医院神经内科

出处《中国医药指南》 2014年第7期46-47,共2页 Guide of China Medicine

关键词帕金森病精神障碍喹硫平 Parkinson＆#39 s disease Mental disorders Quetiapine

分类号 R749 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献7

1Soulas T, Gurruchaga JM,Palfi S,et al.Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease[J].J Neurol Neurosurg Psychiatry,2008,79(8):952-954.
2Kiziltan G,Ozekmekci S,Ertan S,et al.Relationship be tween ageand subtypes ofpsychotic symptoms in Parkinson s disease[J].J Neurol,2007,254(4): 448-452.
3Onofrj M,Thomas A,Bonanni L.New approaches to understanding hallucinations in Parkinson's disease: phenomenology and poss- ible origins[J].Expert Rev Neurother,2007,7(12): 1731 - 1750.
4Miyasaki J,Shannon K,Voon V, et al.Pmctice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neuro- logy,2006,66(7):996.
5Morgante L,Epifanio A,Spina E,et al.Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis[J].Clin Neuro- pharmacol,2004,27(4): 153.
6Juri C,Chana P, Tapia J,et al.Quetiapine for insomnia in Parkinson disease: results from an open-label trial[J].Clin Neuropharmacol, 2005,28(4): 185.
7Miyasaki JM,Sharmon K,Voon VR, et al.Practice Parameter: evalua- tion and treatment of depression,psycho sis,and dementia in Par- kinson disease (an evidencebase dreview): report of the Quality Standards Subcommittee of the American Academy of Neurology [J].Neurology,2006,66(7): 996-1002.